Randomized Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer (KHBO1208)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Biliary cancer; Cholangiocarcinoma
- Focus Therapeutic Use
- 31 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 31 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 20 Mar 2013 Planned End Date 1 Dec 2016 added as reported by ClinicalTrials.gov.